Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San DiegoBusiness Wire • 08/15/23
Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracyte's Decipher Prostate Genomic Classifier in Prostate Cancer TreatmentBusiness Wire • 08/01/23
New Data Suggest Veracyte's Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and CancerBusiness Wire • 06/20/23
New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte's Decipher GRID To Help Advance Molecular Understanding of Prostate CancerBusiness Wire • 05/25/23
New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte's Genomic Tests in Interstitial Lung Disease and Lung CancerBusiness Wire • 05/24/23
Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast CancerBusiness Wire • 05/12/23
Data Published in "The Red Journal” Validate Clinical Utility of Veracyte's Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate CancerBusiness Wire • 05/02/23
Three Abstracts Focusing on the Clinical Utility of Veracyte's Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International ConferenceBusiness Wire • 05/01/23
Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte's Decipher Prostate Genomic ClassifierBusiness Wire • 04/29/23
Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual MeetingBusiness Wire • 04/27/23
Wall Street Analysts See a 40.19% Upside in Veracyte (VCYT): Can the Stock Really Move This High?Zacks Investment Research • 04/27/23
Will Veracyte (VCYT) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 04/27/23
Acuamark Diagnostics Welcomes Giulia Kennedy, Former Chief Scientific and Chief Medical Officer of Veracyte, to its Board of DirectorsBusiness Wire • 04/26/23
New Data Reinforce Ability of Veracyte's Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment IntensificationBusiness Wire • 04/17/23